SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

Hedera (HBAR) is trending due to significant news of the U.S. Military adopting its quantum-secure technology for drones and FedEx joining its Governing Council, signaling strong institutional adoption for real-world asset (RWA) development and utility. The community is actively discussing HBAR's undervalued status and long-term potential, with many accumulating shares despite broader market dips.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix is buzzing with anticipation ahead of pivotal Phase 3 data for its wet AMD treatment, AXPAXLI, expected for presentation at a major scientific conference. This critical readout, coupled with persistent acquisition rumors from Sanofi and the strategic hire of a key commercial leader, has the community keenly discussing the stock's potential for significant re-rating.

This is a legacy token commemorating the pseudonym Satoshi Nakamoto.

Satoshi Nakamoto

$SATOSHI is trending as its community actively champions the tokenization of Satoshi Nakamoto, seeing it as the ultimate embodiment of crypto's foundational identity and a timeless cultural phenomenon. Driven by organic attention and amplified by recent mainstream mentions, many believe it's the "Bitcoin of memes" destined to attract significant retail interest.

Cooper-Standard Holdings, Inc. engages in the manufacture of sealing and fluid handling systems, including fuel and brake delivery and fluid transfer systems. It operates through the following segments: Sealing Systems, Fluid Handling Systems, and Corporate, Eliminations and Other. The Sealing Systems segment consists of manufacturing products for interior vehicle protection, dust and noise intrusion. The Fluid Handling Systems segment includes products that help convey, connect, control, and communicate throughout the fluid systems. The Corporate, Eliminations and Other segment is for all other business activities. The company was founded in 2004 and is headquartered in Northville, MI.

Cooper-Standard Holdings Inc

Cooper-Standard Holdings is trending after reporting strong quarterly earnings that exceeded expectations, highlighting robust operational performance and significant new business awards, particularly in EV and hybrid platforms. The community is buzzing with bullish sentiment around the company's growth trajectory and debt refinancing efforts, though some vocal skeptics point to price action they perceive as manipulation despite improved fundamentals.

Bittensor is an open-source protocol that powers a decentralized, blockchain-based machine learning network. Machine learning models train collaboratively and are rewarded in TAO according to the informational value they offer the collective. TAO also grants external access, allowing users to extract information from the network while tuning its activities to their needs.  Ultimately, BitTensors vision is to create a pure market for artificial intelligence, an incentivized arena in which consumers and producers of this valuable commodity can interact in a trustless, open and transparent context.  Bittensor enables:  -A novel, optimized strategy for the development and distribution of artificial intelligence technology by leveraging the possibilities of a distributed ledger. Specifically, its facilitation of open access/ownership, decentralized governance, and the ability to harness globally-distributed resources of computing power and innovation within an incentivized framework.  -An open-source repository of machine intelligence, accessible to anyone, anywhere, thus creating the conditions for open and permission-less innovation on a global internet scale.  -Distribution of rewards and network ownership to users in direct proportion to the value they have added.

Bittensor

Bittensor (TAO CRYPTO) is trending as the community anticipates its upcoming halving event and a Grayscale ETF filing, reinforcing its narrative as the "Bitcoin of AI" within the decentralized AI sector and sparking widespread discussion about its long-term scarcity and staking opportunities.

Venice boasts an innovative approach to generative AI with its unique privacy architecture, access to competitive features including multiple leading open-source LLM models such as DeepSeek R1, PDFs analysis, and image and code generation. An unrestricted AI Characters feature is available with its Pro version, Venice Pro.   VVV is designed to minimize friction and reduce costs for AI agents and developers to access private, reliable, on-demand and perpetual AI inference via Venice.ai's API.

Venice Token

Venice Token (VVV) is experiencing significant community attention following substantial token burns and the rollout of new features like video generation and DIEM token minting. Enthusiastic discussions highlight its low circulating supply, attractive staking rewards, and unique private AI utility, particularly after recent exchange listings.

Visa, Inc. engages in the provision of digital payment services. It also facilitates global commerce through the transfer of value and information among a global network of consumers, merchants, financial institutions, businesses, strategic partners, and government entities. It offers debit cards, credit cards, prepaid products, commercial payment solutions, and global automated teller machines. The company was founded by Dee Hock in 1958 and is headquartered in San Francisco, CA.

Visa Inc - Ordinary Shares - Class A

Visa Inc

Visa is trending amid significant market debate over potential regulatory changes, including a proposed credit card interest rate cap and new legislation, which are overshadowing its recent Q1 earnings beat. The community is actively discussing whether these threats will materially impact Visa's transaction-based revenue or are merely political posturing.

English version Introducing SWFTCoin (SWFTC) $SWFTC: Powering SWFT Blockchain and AI Services (SWFTGPT)  SwftCoin ($SWFTC) is the native utility token driving SWFT Blockchain's AI-powered ecosystem, SWFTGPT, and the first ever AI token featured on Coinbase. SWFTGPT is also the first domain-specific LLM for crypto.  SwftCoin key features include: 50% Reduced Transaction Fees: Lower costs on all transactions. AI Service Payments: Use $SWFTC to access SWFTGPT. Tools include expert market analysis,  predictions, and intelligent trading solutions.  Membership Benefits: Unlock premium features and AI agent services within SWFTGPT. AI-Powered Swaps: Enable precise, fast cross-chain transactions and analytics. SWFT Blockchain combines AI innovation with blockchain infrastructure, simplifying crypto trading while enhancing functionality through $SWFTC.   Chinese version $SWFTC：驱动 SWFT Blockchain 和 AI 服务（SWFTGPT） SwftCoin ($SWFTC) 是 SWFT Blockchain 的原生实用代币，为其 AI 驱动的生态系统 SWFTGPT 提供支持，同时也是 Coinbase 上首个 AI 代币。SWFTGPT 也是首个专注于加密领域的特定领域大型语言模型 (LLM)。 SwftCoin 的主要功能包括： 1、50% 交易费减免：降低所有交易成本。 2、AI 服务支付：使用 $SWFTC 访问 SWFTGPT 工具，包括专家市场分析、预测以及智能交易解决方案。 3、会员权益：解锁 SWFTGPT 的高级功能和 AI 代理服务。 4、AI 驱动的闪兑：实现精准快速的跨链交易和数据分析。 SWFT Blockchain 将 AI 创新与区块链基础设施结合，通过 $SWFTC 简化加密交易，并提升其功能性。

SwftCoin

SwftCoin (SWFTC) is trending as the community actively discusses its significant potential, fueled by its perceived undervaluation as an AI-integrated cross-chain exchange with a fully diluted, fixed supply, prompting many to anticipate a major breakout reminiscent of its past parabolic movements.

One Stop Systems, Inc. engages in the design, manufacture, and marketing of computing modules and systems targeting edge deployments. It deals with the design and manufacture of high-performance customized computer and flash arrays, in-flight entertainment, and connectivity and value-added reseller with minimal customization. It operates through the OSS and OSS Europe segments. The company was founded by Stephen D. Cooper and Mark Gunn in 1998 and is headquartered in Escondido, CA.

One Stop Systems Inc

One Stop Systems is trending due to significant insider buying and recent contract wins in commercial robotics and aerospace, fueling community speculation about a larger impending defense contract. Investors are actively discussing its undervaluation as a key player in rugged Edge AI compute, with a small float that many believe could lead to substantial long-term gains despite broader market volatility.

ProShares Trust - ProShares UltraPro Short QQQ -3x Shares

ProShares UltraPro Short QQQ

ProShares UltraPro Short QQQ (SQQQ) is trending as the community actively discusses hedging against an anticipated market downturn, fueled by ongoing concerns over geopolitical tensions, potential weakness in the AI sector, and a hawkish Federal Reserve stance. Traders are speculating on further declines for the Nasdaq 100, seeing SQQQ as a key play for bearish exposure.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$IPSC vs $SANA vs $VXRT vs $CRSP vs other (?) for T1DM cure??
$XBI

Michael

StockTwits For Android 

Century Therapeutics Inc

Sana Biotechnology Inc

Vaxart Inc

CRISPR Therapeutics AG

SPDR S&P Biotech ETF

uniQure NV

Cidara Therapeutics Inc

Capricor Therapeutics Inc

Quoin Pharmaceuticals Ltd - ADR

Applied Therapeutics Inc

Evaxion Biotech

Neuphoria Therapeutics Inc.

Biotech Pharma Investor

StockTwits for iOS

American Battery Technology Company

NIO Inc

Nu Holdings Ltd

Livewire Ergogenics Inc

Archer Aviation Inc

BONK

Scrapps

@Biotech_Pharma_Investor @Scrapps64 IPSC nor LCTX havent tested their hypo line in a human yet, and it&#39;s quite a ways to even get to that point.  VXRT I have never heard of, if you meant vrtx, vrtx is in the lead to getting vx880 to patients, however not many T1D&#39;s can trade insulin injections for the price of immunosuppression. While life would be easier not dealing with diabetes, it would most likely be a shorter life, and with current IS, namely tacrolimus, toxic to the body/organs.   ELDN has tego, which is testing to be nontoxic; they have also cured about 13 T1D patients using their IS platform.  CRSP has been developing CTX211, formerly known as VCTX211 when it was in collab with vrtx, however vrtx dropped the collab - that should tell you how it&#39;s going.  Kadimastem is working with itolerance to encapsulate islets, and the gel they are using is fascinating, but encapsulation is a tough nut to crack (TASE: KDST).Other companies too. 
 
Sana has islets with no IS working in a human.

StockTwits Web

 IPSC nor LCTX havent tested their hypo line in a human yet, and it's quite a ways to even get to that point.  VXRT I have never heard of, if you meant vrtx, vrtx is in the lead to getting vx880 to patients, however not many T1D's can trade insulin injections for the price of immunosuppression. While life would be easier not dealing with diabetes, it would most likely be a shorter life, and with current IS, namely tacrolimus, toxic to the body/organs.   ELDN has tego, which is testing to be nontoxic; they have also cured about 13 T1D patients using their IS platform.  CRSP has been developing CTX211, formerly known as VCTX211 when it was in collab with vrtx, however vrtx dropped the collab - that should tell you how it's going.  Kadimastem is working with itolerance to encapsulate islets, and the gel they are using is fascinating, but encapsulation is a tough nut to crack (TASE: KDST).Other companies too. 
 
Sana has islets with no IS working in a human.

Dexcom Inc

Vertex Pharmaceuticals, Inc.

Eledon Pharmaceuticals Inc

Sensei Biotherapeutics Inc

iSpecimen Inc

Brian H.

@BriOnH @Scrapps64 
Yes I meant VRTX
CTX211 seems dead, yes (now CRSP moving to CTX213).
Physical barrier methods aiming to obviate IS supression have failed
Hypoimmune seems to be the future (if it will work)

Btw has SANA clarified how they plan to administer their treatment IM in the ph1? (PoC published in NEJM was with a tiny dose, which still was given with 17 injections).

PS: Sernova is also collaboraring with ELDN

 
Yes I meant VRTX
CTX211 seems dead, yes (now CRSP moving to CTX213).
Physical barrier methods aiming to obviate IS supression have failed
Hypoimmune seems to be the future (if it will work)

Btw has SANA clarified how they plan to administer their treatment IM in the ph1? (PoC published in NEJM was with a tiny dose, which still was given with 17 injections).

PS: Sernova is also collaboraring with ELDN

@Biotech_Pharma_Investor @Scrapps64 Well hypoimmune islets, albeit in 1 patient _is_ working.  The hypoimmune tech also worked in about 12 other individuals in sc291, but sc291 is outside of my wheelhouse, t1d is my wheelhouse.   
 
My current understanding is Sana is hypothesizing ways to make delivery to the patient as easy as possible.  Not too long ago I kept asking why they aren&#39;t using the Edmonton Protocol, but the reason why is because it requires more doctors, more specialization, and more work.  I believe they are strategizing a middle ground between IM and EP, but I may be outdated on this. 
 
In one of my old brokerages I have some super small position somewhere in servnova, their CEO has an interesting story too, but encapsulation has been such a letdown that has never worked.  Can it?  idk/doubt it, but itolerances gel does look interesting.

 Well hypoimmune islets, albeit in 1 patient _is_ working.  The hypoimmune tech also worked in about 12 other individuals in sc291, but sc291 is outside of my wheelhouse, t1d is my wheelhouse.   
 
My current understanding is Sana is hypothesizing ways to make delivery to the patient as easy as possible.  Not too long ago I kept asking why they aren't using the Edmonton Protocol, but the reason why is because it requires more doctors, more specialization, and more work.  I believe they are strategizing a middle ground between IM and EP, but I may be outdated on this. 
 
In one of my old brokerages I have some super small position somewhere in servnova, their CEO has an interesting story too, but encapsulation has been such a letdown that has never worked.  Can it?  idk/doubt it, but itolerances gel does look interesting.